BLTE insider buying and SEC filings, explained
Belite Bio, Inc. · CIK 1889109
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$2.9M
Planned sales (10b5-1)
$37.8M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 1, 2026 | Planned (10b5-1) | Hendrik Peter Scholl (Chief Medical Officer) sold 500 shares indirectly at about $165.32 ($83K), marked as a 10b5-1 plan trade. Indirect holdings down 3% to 14,500 shares. | SEC filing Filed Oct 5, 2026, 7:27 PM ET |
| Sep 4–8, 2026 | Planned (10b5-1) | Yu-Hsin Lin (CEO and Director) sold 100,435 shares between Sep 4 and Sep 8 at about $190.00 ($19.1M), marked as a 10b5-1 plan trade. Holdings down 59% to 70,134 shares. | SEC filing Filed Sep 9, 2026 |
| Sep 4–8, 2026 | Planned (10b5-1) | Hao-Yuan Chuang (CFO and Director) sold 67,395 shares between Sep 4 and Sep 8 at about $189.98 ($12.8M), marked as a 10b5-1 plan trade. Holdings down 72% to 26,038 shares. | SEC filing Filed Sep 9, 2026 |
| Aug 12, 2026 | Planned (10b5-1) | Hao-Yuan Chuang (CFO and Director) sold 367 shares at about $180.35 ($66K), marked as a 10b5-1 plan trade. Holdings down <1% to 93,433 shares. | SEC filing Filed Aug 14, 2026 |
| Aug 12, 2026 | Planned (10b5-1) | Yu-Hsin Lin (CEO and Director) sold 365 shares at about $180.35 ($66K), marked as a 10b5-1 plan trade. Holdings down <1% to 170,569 shares. | SEC filing Filed Aug 14, 2026 |
| Jun 18, 2026 | Sale | Hendrik Peter Scholl (Chief Medical Officer) sold 10,000 shares indirectly at about $145.24 ($1.5M). Indirect holdings down 40% to 15,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 22, 2026 |
| Jun 16, 2026 | Sale | Hendrik Peter Scholl (Chief Medical Officer) sold 10,000 shares indirectly at about $140.57 ($1.4M). Indirect holdings down 29% to 25,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 17, 2026 |
| May 7, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 666 shares at about $153.21 ($102K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed May 8, 2026 |
| May 6, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $153.84 ($154K), marked as a 10b5-1 plan trade. Holdings down 60% to 666 shares. | SEC filing Filed May 7, 2026 |
| May 5, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $155.50 ($156K), marked as a 10b5-1 plan trade. Holdings down 38% to 1,666 shares. | SEC filing Filed May 6, 2026 |
| May 4, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $155.64 ($156K), marked as a 10b5-1 plan trade. Holdings down 27% to 2,666 shares. | SEC filing Filed May 5, 2026 |
| May 1, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $155.78 ($156K), marked as a 10b5-1 plan trade. Holdings down 21% to 3,666 shares. | SEC filing Filed May 4, 2026 |
| Apr 30, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $156.97 ($157K), marked as a 10b5-1 plan trade. Holdings down 18% to 4,666 shares. | SEC filing Filed May 1, 2026 |
| Apr 29, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $155.82 ($156K), marked as a 10b5-1 plan trade. Holdings down 15% to 5,666 shares. | SEC filing Filed Apr 30, 2026 |
| Apr 28, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $159.16 ($159K), marked as a 10b5-1 plan trade. Holdings down 13% to 6,666 shares. | SEC filing Filed Apr 29, 2026 |
| Apr 27, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $162.64 ($163K), marked as a 10b5-1 plan trade. Holdings down 12% to 7,666 shares. | SEC filing Filed Apr 28, 2026 |
| Apr 24, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $159.56 ($160K), marked as a 10b5-1 plan trade. Holdings down 10% to 8,666 shares. | SEC filing Filed Apr 27, 2026 |
| Apr 23, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $166.28 ($166K), marked as a 10b5-1 plan trade. Holdings down 9% to 9,666 shares. | SEC filing Filed Apr 24, 2026 |
| Apr 22, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $170.39 ($170K), marked as a 10b5-1 plan trade. Holdings down 9% to 10,666 shares. | SEC filing Filed Apr 23, 2026 |
| Apr 21, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $166.00 ($166K), marked as a 10b5-1 plan trade. Holdings down 8% to 11,666 shares. | SEC filing Filed Apr 22, 2026 |
| Apr 20, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $163.60 ($164K), marked as a 10b5-1 plan trade. Holdings down 7% to 12,666 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 17, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $161.63 ($162K), marked as a 10b5-1 plan trade. Holdings down 7% to 13,666 shares. | SEC filing Filed Apr 20, 2026 |
| Apr 16, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $160.38 ($160K), marked as a 10b5-1 plan trade. Holdings down 6% to 14,666 shares. | SEC filing Filed Apr 20, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Nathan L. Mata (Chief Scientific Officer) sold 1,000 shares at about $168.30 ($168K), marked as a 10b5-1 plan trade. Holdings down 6% to 15,666 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 9, 2026 | Planned (10b5-1) | Yu-Hsin Lin (CEO and Director) sold 9,200 shares at about $181.45 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 5% to 170,934 shares. | SEC filing Filed Apr 13, 2026 |
| Apr 9, 2026 | Planned (10b5-1) | Wan-Shan Chen (Director) sold 1,100 shares at $180.43 ($198K), marked as a 10b5-1 plan trade. Holdings down 11% to 9,096 shares. | SEC filing Filed Apr 13, 2026 |
| Apr 9, 2026 | Planned (10b5-1) | Hao-Yuan Chuang (CFO and Director) sold 6,200 shares at about $181.50 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 6% to 93,800 shares. | SEC filing Filed Apr 13, 2026 |
10 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow BLTE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.